DIGI-INTERNATIONAL
21.6.2022 09:02:08 CEST | Business Wire | Press release
Digi International ® , (NASDAQ: DGII) - a leading global provider of Internet of Things (IoT) connectivity products, solutions, services and wireless data plans - today announced it will showcase a wide range of its new solutions and devices at Embedded World 2022 that enable medical, transportation, agriculture and industrial enterprises to create innovative solutions faster.
Digi’s first-look of its Digi ConnectCore MP1 system-on-modules, Digi ConnectCore Voice Control software, and Digi XBee Intelligent Edge Controller takes place at Bressner Technology booth 1-236 in Hall 1. Digi ConnectCore MP1 is also on display at STMicroelectronics Wall of SOMs booth 4A-148. There are live demos of Digi XBee and its IX15 gateway and the new Digi ConnectCore Voice Control application at the NXP booth 4A-222.
Bolstered by Digi Remote Manager® —the command center of an intelligent network—Digi’s new and smaller embedded IoT technologies dramatically improve the way people, machines and processes interact. Network connectivity is the fundamental key to the true potential of these technologies that place Digi at the forefront of some of the most advanced networking solutions combining software, hardware and services for enterprises.
“This is an exceptionally exciting year to return to Embedded World,” said Andreas Burghart, Senior Product Manager at Digi. “Advances in connectivity and IoT devices are spurring the rapid development of next-generation, cost-effective, integrated solutions. That’s unleashing new waves of innovation across numerous industries that require reliable and secure connectivity. We’re looking forward to sharing our progress and collaborating with our customers on breakthrough embedded solutions.”
Digi’s Embedded World 2022 solution showcase includes three new or recently launched products:
- Digi ConnectCore® MP1 Family – The Digi ConnectCore® MP1 family of system-on-modules (SOMs) features the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility. The solution also features its Connected Device platform and well-tested development tools and design support. Digi ConnectCore MP1 SOMs offer a cost-effective wireless solution for OEMs seeking to reduce product-development risk and effort.
- Digi ConnectCore Voice Control Software – This advanced voice-control software solution is designed for the acclaimed ConnectCore family of system-on-modules (SOMs). Digi ConnectCore Voice Control is a fully integrated, ready-to use software solution that enables developers to design a voice-based human-machine interface (HMI) to control device operations using speech. It provides voice processing on edge devices (including support for 30 languages and a 60,000-word vocabulary) with no cloud connectivity required. That reduces connectivity costs and data-privacy concerns while providing response times of less than 100ms.
- Digi XBee® Intelligent Edge Controller (IEC) - The Digi XBee® Intelligent Edge Controller (IEC) delivers a comprehensive networking architecture to close the gap between field devices and the cloud and provide powerful asset monitoring and control. In combination with Digi X-ON cloud, the Digi XBee IEC helps companies monitor sensors or remote-control assets over long-range, low-power wide area networks, including LoRaWAN, CAT-M1, and NB-IoT. Industrial devices can be monitored with sub-second latency with alarms and data wirelessly delivered through the Digi X-ON cloud.
At Embedded World, Digi will also demonstrate its wireless IoT solution for smart agriculture with a simulation of a complete ecosystem that can centrally manage multiple farms. This end-to-end solution provides crop managers with real-time weather conditions that help determine optimal irrigation cycles, maximize crop yields and lower labor and supply costs. The heart of the system is the Digi IX15 gateway and cellular router that communicates with irrigation pumps through a wireless mesh network of Digi XBee® modules. Using Digi Remote Manager® and a cloud-based web application, a crop manager monitors exact weather and soil conditions at each farm, and controls individual pumps. The commands pass through the internet to the IX15 by a cellular network, and the IX15 relays the commands to the XBee modules at each pump, turning them on and off remotely.
Digi will also preview its upcoming Digi ConnectCore 93, which includes NXP’s i.MX 93 system-on-a-chip (SOC). Digi is one of six Early Access Partners for this April 2023 release.
For more information about Digi, stop by Bresser Technology Booth 1-236 in Hall 1 or visit: www.digi.com .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005096/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom